Abstract
The centrally active, alpha-2 adrenergic receptor agonist Clonidine was given to 12 spinal cord injury patients with problematic spasticity not adequately controlled by recognized spasmolytic drug therapy. Five patients had an excellent reduction and 2 patients had some reduction in clinical spasticity (average dose 0.39 mg daily). Four of the 7 responders discontinued Clonidine because of adverse reactions after an average of ten weeks of therapy. Three responders have continued to tolerate the drug well with excellent control of spasticity for 18 to 34 months. Five patients had no change in clinical spasticity (average dose of 0.24 mg daily). Three of the non-responders discontinued Clonidine because of adverse reactions after an average of three weeks of therapy. Significant associated adverse reactions included syncopal seizures (3), cerebrovascular accident (1), deep vein thrombosis (1), autonomic hyperreflexia (3), lethargy/drowsiness (3), and nausea/vomiting (1). Possible mechanisms of action for Clonidine to affect spasticity and the unstable cardiovascular system of quadriplegics is discussed. While spinal cord injured patients with severe spasticity may benefit from Clonidine, great caution is recommended during its use until further study establishes safe parameters of administration and efficacy is confirmed on controlled studies.
Similar content being viewed by others
Article PDF
References
Garrett B N, Kaplan N M 1980 Clonidine in the Treatment of Hypertension. Journal of Cardiovascular Pharmacology 2: 61–71.
Gold M S, Pottash A C Sweeney D R, Kleber H D 1980 Opiate Withdrawal Using Clonidine. A Safe, Effective and Rapid Nonopiate Treatement. Journal of American Medical Association 243 4: 343–346.
Guthrie G P, Kotchen, T 1983 Effects of Oral Clonidine on Baroreceptor Function in Patients with Essential Hypertension. Chest 38 No. 2 supplement February.
Hoffman B B, Lefkowitz R J 1980 Alpha-Adrenergic Receptor Subtypes. New England Journal of Medicine 302: 1390–1396.
Isasc L 1980 Clonidine in the Central Nervous System: Site and Mechanism of Hypotensive Action. Journal of Cardiovascular Pharmacology 2:5-19 Supplement 1.
Naftchi N E, Kirschner A K, Demeny M, Viau A 1982 Changes in the CNS Biogenic Amines and Tyrosine Hydroxylase Activity after Spinal Cord Transection in the Rat. Spinal Cord Injury, ed. NE Naftchi, Spectrum Publications, Inc., New York Chapter 5, pp 67–80.
Pettinger W A 1980 Pharmacology of Clonidine. Journal of Cardiovascular Pharmacology 2:61-71 Supplement 1.
Reid J L, Wing L M H, Mathias C J, Frankel H L, Neill, E 1977 The Central Hypertensive Effect of Clonidine: Studies in Tetraplegic Subjects. Clinical Pharmacologic Therapy 21: 375–382.
Tuckman J, Chu D S, Petrillo C R, Naftchi N E 1982 Clinical Trial of an Alpha Adrenergic Receptor Stimulating Drug (Clonidine) for Treatment of Spasticity in Spinal Cord Injured Patients. Spinal Cord Injured, ed. NE Naftchi, Spectrum Publications, Inc., New York, Chapter 10, page 133.
Tollefson G D 1981 Hyperadrenergic Hypomania Consequent to the Abrupt Cessation of Clonidine. Journal of Clinical Psychopharmacology 1, 2: 93–95.
Young R R, Delwide P J 1981 Drug Therapy, Spasticity. New England Journal of Medicine 304: 28-33, 96–99.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Maynard, F. Early clinical experience with clonidine in spinal spasticity. Spinal Cord 24, 175–182 (1986). https://doi.org/10.1038/sc.1986.24
Issue Date:
DOI: https://doi.org/10.1038/sc.1986.24